FDA Clears Wandercraft's Exoskeleton for Rehabilitation of Stroke Patients

FDA Clears Wandercraft’s Exoskeleton for Rehabilitation of Stroke Patients

Stroke victims in the United States may soon be able to benefit from cutting-edge robotics throughout their rehabilitation. Wandercraft’s Atalante exoskeleton has been certified for use in stroke therapy by the Food and Drug Administration. The machine may aid in intense gait training, especially for persons with restricted upper body movement who may be unable to use conventional approaches.

The current-generation Atalante is a self-balancing, battery-powered gadget with an adjustable gait that may assist with early steps and later in treatment, more natural walking. While the hardware must still be utilised in a therapeutic environment with the assistance of a therapist, its hands-free usage allows patients to restore their gait regardless of whether they can use their arms.

Wandercraft intends to ship its first exoskeletons to the United States in the first quarter of this year, but has not named any early clients. Although it has just recently begun doing business in the nation, financial backer Quadrant Management believes Wandercraft will be able to “substantially grow” its activities over the next one to two years.

FDA-approved exoskeletons are currently uncommon and confined to treating particular ailments. Ekso Bionics gained approval to commercialise their EksoNR device for multiple sclerosis rehab in June. Wandercraft’s clearance makes the technology available to a broader spectrum of patients, which may be particularly beneficial given that strokes are a leading cause of long-term impairment in the United States. Every year, around 795,000 individuals in the United States have a stroke; this might help some of them recover their mobility.